Literature DB >> 26646908

Optimization and Dose Estimation of Aerosol Delivery to Non-Human Primates.

Ronan J MacLoughlin1, Geert van Amerongen2, James B Fink3, Hettie M Janssens4, W Paul Duprex5, Rik L de Swart2.   

Abstract

BACKGROUND: In pre-clinical animal studies, the uniformity of dosing across subjects and routes of administration is a crucial requirement. In preparation for a study in which aerosolized live-attenuated measles virus vaccine was administered to cynomolgus monkeys (Macaca fascicularis) by inhalation, we assessed the percentage of a nebulized dose inhaled under varying conditions.
METHODS: Drug delivery varies with breathing parameters. Therefore we determined macaque breathing patterns (tidal volume, breathing frequency, and inspiratory to expiratory (I:E) ratio) across a range of 3.3-6.5 kg body weight, using a pediatric pneumotachometer interfaced either with an endotracheal tube or a facemask. Subsequently, these breathing patterns were reproduced using a breathing simulator attached to a filter to collect the inhaled dose. Albuterol was nebulized using a vibrating mesh nebulizer and the percentage inhaled dose was determined by extraction of drug from the filter and subsequent quantification.
RESULTS: Tidal volumes ranged from 24 to 46 mL, breathing frequencies from 19 to 31 breaths per minute and I:E ratios from 0.7 to 1.6. A small pediatric resuscitation mask was identified as the best fitting interface between animal and pneumotachometer. The average efficiency of inhaled dose delivery was 32.1% (standard deviation 7.5, range 24%-48%), with variation in tidal volumes as the most important determinant.
CONCLUSIONS: Studies in non-human primates aimed at comparing aerosol delivery with other routes of administration should take both the inter-subject variation and relatively low efficiency of delivery to these low body weight mammals into account.

Entities:  

Keywords:  cynomolgus macaques; inhaled dose; non-human primates; tidal breathing; vibrating mesh nebulizer

Mesh:

Substances:

Year:  2015        PMID: 26646908     DOI: 10.1089/jamp.2015.1250

Source DB:  PubMed          Journal:  J Aerosol Med Pulm Drug Deliv        ISSN: 1941-2711            Impact factor:   2.849


  9 in total

1.  Aerosolized recombinant human butyrylcholinesterase delivered by a nebulizer provides long term protection against inhaled paraoxon in macaques.

Authors:  Yvonne Rosenberg; James Fink; Ronan MacLoughlin; Tara Ooms-Konecny; Dennis Sullivan; William Gerk; Lingjun Mao; Xiaoming Jiang; Jonathan Lees; Lori Urban; Narayanan Rajendran
Journal:  Chem Biol Interact       Date:  2019-06-12       Impact factor: 5.192

Review 2.  Acetylcholinesterase inhibition resulting from exposure to inhaled OP can be prevented by pretreatment with BChE in both macaques and minipigs.

Authors:  Yvonne Rosenberg; Ashima Saxena
Journal:  Neuropharmacology       Date:  2020-05-19       Impact factor: 5.250

3.  Post-exposure treatment with the oxime RS194B rapidly reactivates and reverses advanced symptoms of lethal inhaled paraoxon in macaques.

Authors:  Yvonne J Rosenberg; Jerry Wang; Tara Ooms; Narayanan Rajendran; Lingjun Mao; Xiaoming Jiang; Jonathan Lees; Lori Urban; Jeremiah D Momper; Yadira Sepulveda; Yan-Jye Shyong; Palmer Taylor
Journal:  Toxicol Lett       Date:  2017-11-09       Impact factor: 4.372

4.  Nebulized fusion inhibitory peptide protects cynomolgus macaques from measles virus infection.

Authors:  Olivier Reynard; Claudia Gonzalez; Claire Dumont; Mathieu Iampietro; Marion Ferren; Sandrine Le Guellec; Laurie Lajoie; Cyrille Mathieu; Gabrielle Carpentier; Georges Roseau; Francesca Bovier; Yun Zhu; Deborah Le Pennec; Jerome Montharu; Amin Addetia; Alexander Greninger; Christopher Alabi; Anne Moscona; Laurent Vecellio; Matteo Porotto; Branka Horvat
Journal:  Res Sq       Date:  2022-06-01

Review 5.  Creation of a protective pulmonary bioshield against inhaled organophosphates using an aerosolized bioscavenger.

Authors:  Yvonne J Rosenberg; James B Fink
Journal:  Ann N Y Acad Sci       Date:  2016-07-02       Impact factor: 5.691

Review 6.  Perspective on Global Measles Epidemiology and Control and the Role of Novel Vaccination Strategies.

Authors:  Melissa M Coughlin; Andrew S Beck; Bettina Bankamp; Paul A Rota
Journal:  Viruses       Date:  2017-01-19       Impact factor: 5.048

7.  Modified Vaccinia Virus Ankara Preferentially Targets Antigen Presenting Cells In Vitro, Ex Vivo and In Vivo.

Authors:  Arwen F Altenburg; Carolien E van de Sandt; Bobby W S Li; Ronan J MacLoughlin; Ron A M Fouchier; Geert van Amerongen; Asisa Volz; Rudi W Hendriks; Rik L de Swart; Gerd Sutter; Guus F Rimmelzwaan; Rory D de Vries
Journal:  Sci Rep       Date:  2017-08-17       Impact factor: 4.379

8.  In Vitro Study of the Effect of Breathing Pattern on Aerosol Delivery During High-Flow Nasal Therapy.

Authors:  Gavin Bennett; Mary Joyce; Louise Sweeney; Ronan MacLoughlin
Journal:  Pulm Ther       Date:  2019-02-06

9.  Needle-free delivery of measles virus vaccine to the lower respiratory tract of non-human primates elicits optimal immunity and protection.

Authors:  Rik L de Swart; Rory D de Vries; Linda J Rennick; Geert van Amerongen; Stephen McQuaid; R Joyce Verburgh; Selma Yüksel; Alwin de Jong; Ken Lemon; D Tien Nguyen; Martin Ludlow; Albert D M E Osterhaus; W Paul Duprex
Journal:  NPJ Vaccines       Date:  2017-08-01       Impact factor: 7.344

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.